TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19567799

Group type: EXPERIMENTAL
Intervention: Laptop computer
Number of subjects: 160

Group type: COMPARATOR
Intervention: Handheld computer
Number of subjects: 160
Study: 17935545

Group type: EXPERIMENTAL
Intervention: 20 mg of lovastatin plus 10 g of psyllium
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 mg of lovastatin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10 g of psyllium
Number of subjects: 36
Study: 15465203

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) followed by conventional external beam radiation therapy (EBRT) with carmustine (BCNU)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Conventional external beam radiation therapy (EBRT) with carmustine (BCNU) alone
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) followed by EBRT with BCNU
Number of subjects: 203
Study: 11755954

Group type: EXPERIMENTAL
Intervention: Ancrod (1.0, 1.5, and 2.0 IU/kg body weight)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10036657

Group type: EXPERIMENTAL
Intervention: UCLP group
Number of subjects: 143

Group type: COMPARATOR
Intervention: NCC group
Number of subjects: 143
Study: 7748845

Group type: EXPERIMENTAL
Intervention: Behaviour modification programme including dental examinations, visits by dental hygienists, and contracts with children and parents
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was provided)
Number of subjects: 16
Study: 2899496

Group type: EXPERIMENTAL
Intervention: Cefotaxime and metronidazole (75 mg/kg and 10 mg/kg intravenously in 3 doses at 12-hourly intervals) administered preoperatively or perioperatively (group 1)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Cefotaxime and metronidazole (75 mg/kg and 10 mg/kg intravenously in 3 doses at 12-hourly intervals) plus peritoneal lavage with cefotaxime 2 g/L during surgery (group 2)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Non-lavage group (group 1)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Lavage group (group 2)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 401
Study: 31141634

Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 881

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 881
Study: 28552790

Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST)
Number of subjects: 25
Study: 25466655

Group type: EXPERIMENTAL
Intervention: Glutamine 30 g/d (10 g powder, three times a day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 23073982

Group type: EXPERIMENTAL
Intervention: ZAP questionnaire (modified version)
Number of subjects: 1773
Study: 21929769

Group type: EXPERIMENTAL
Intervention: iCPR tool
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control (simulated group)
Number of subjects: 149
Study: 18060377

Group type: EXPERIMENTAL
Intervention: Compliance-enhancing program in patients with statin therapy
Number of subjects: 7640
Study: 16836480

Group type: COMPARATOR
Intervention: Positive information about one novel animal; Negative information about another novel animal; No information about a third animal.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pictorial dot-probe task (immediate and 24-hr delay)
Number of subjects: 0
Study: 14656779

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg*kg(‐1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.2 mg*kg(‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study: 10738435

Group type: EXPERIMENTAL
Intervention: Antibiotic beads
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional intravenous antibiotics
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Antibiotic beads and intravenous antibiotics (nonrandomized third cohort)
Number of subjects: 67
Study: 9183501

Group type: EXPERIMENTAL
Intervention: Alcohol expectancy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 64

Group type: COMPARATOR
Intervention: Expectancy of alcohol (in males)
Number of subjects: 64
Study: 1279634

Group type: EXPERIMENTAL
Intervention: Substance P (1.5 pmol/kg-1/min-1 over 60 min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Substance P (0.5 pmol/kg-1/min-1 over 60 min)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Substance P (1 pmol/kg-1/min-1 over 60 min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: GH-RH (1 micrograms/kg body weight in an IV bolus) during saline infusion
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: GH-RH (1 micrograms/kg body weight in an IV bolus) during SP infusion
Number of subjects: 14
Study: 2987294

Group type: EXPERIMENTAL
Intervention: Prednisone (glucocorticoid therapy)
Number of subjects: 14
Study: 30669640

Group type: EXPERIMENTAL
Intervention: Mountain hiking in an environment with less anthropogenic elements
Number of subjects: 52

Group type: COMPARATOR
Intervention: Mountain hiking in an environment with more anthropogenic elements
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Mountain hiking (both conditions)
Number of subjects: 52
Study: 30217229

Group type: EXPERIMENTAL
Intervention: Probiotic and selenium co-supplementation (8×10^9 CFU/day probiotic plus 200 μg/day selenium)
Number of subjects: 60
Study: 26946962

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: SNP rs11649514 in PRKCB
Number of subjects: 232
Study: 25338248

Group type: EXPERIMENTAL
Intervention: Massage by acupressure
Number of subjects: 45

Group type: COMPARATOR
Intervention: Garlium Arseneid Laser 904 nm turned off (placebo)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 45
Study: 21777283

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 693

Group type: COMPARATOR
Intervention: Magnifying chromoendoscopy (MCE)
Number of subjects: 693
Study: 20191831

Group type: EXPERIMENTAL
Intervention: Frozen section exam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 0
Study: 17275150

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Number of subjects: 19
Study: 14665500

Group type: EXPERIMENTAL
Intervention: Modafinil (200 to 400 mg qd)
Number of subjects: 125
Study: 11009043

Group type: EXPERIMENTAL
Intervention: Formoterol (13.5 + 13.5 + 27 microg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Salbutamol (300 + 300 + 600 microg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Formoterol (9 microg twice daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Salbutamol (900 + 900 + 1800 microg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 23
Study: 10451943

Group type: EXPERIMENTAL
Intervention: LMWH (fraxiparin) 60 anti Xa IU.kg‐1.day‐1 plus steroid, cyclophosphamide, and bennazipril
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (steroid, cyclophosphamide, and bennazipril)
Number of subjects: 41
Study: 1589566

Group type: EXPERIMENTAL
Intervention: Zolpidem (20 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2423333

Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg IV followed by 100 mg twice daily for 15 days)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 31517823

Group type: EXPERIMENTAL
Intervention: Dangguijakyaksan
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 29417761

Group type: EXPERIMENTAL
Intervention: M923 (40 mg)
Number of subjects: 315

Group type: COMPARATOR
Intervention: US Humira
Number of subjects: 315

Group type: COMPARATOR
Intervention: EU Humira
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: M923
Number of subjects: 315
Study: 27468258

Group type: EXPERIMENTAL
Intervention: BCAAs and CHO (3 g/d L-leucine, 1 g/d L-isoleucine, 2 g/d L-valine with 2 g of CHO; n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CHO only (42 g of CHO; n=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BCAAs and CHO
Number of subjects: 30

Group type: COMPARATOR
Intervention: CHO only
Number of subjects: 30
Study: 25372381

Group type: EXPERIMENTAL
Intervention: Exercise (30 min on a treadmill at ventilatory threshold intensity)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (seated for 150 min)
Number of subjects: 9
Study: 22961772

Group type: EXPERIMENTAL
Intervention: Incongruent affect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flat affect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affective deviants (targets with non-normative reactions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normative reactions (control group)
Number of subjects: 0
Study: 20645530

Group type: COMPARATOR
Intervention: Ustekinumab 22.5 or 45 mg/kg s.c. (n = 32)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ustekinumab 0.09-4.5 mg/kg i.v. or 0.27-2.7 mg/kg s.c. (n = 46)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ustekinumab (n = 20)
Number of subjects: 54
Study: 18393008

Group type: EXPERIMENTAL
Intervention: Maternal perception of fetal movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formal fetal movement counting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Defined limits for reduced fetal movements in a low risk population
Number of subjects: 0
Study: 16288390

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF) 400 mg once daily intravenously, possibly followed by oral tablets
Number of subjects: 397

Group type: COMPARATOR
Intervention: Ceftriaxone (CTRX) 2 g intravenously once daily with or without Erythromycin (ERY) 1 g intravenously every 6-8 h
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Ceftriaxone (CTRX) with or without Erythromycin (ERY)
Number of subjects: 397
Study: 12855386

Group type: EXPERIMENTAL
Intervention: Version 1 (attributed lower forecast income of women to intrinsic gender factors)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Version 2 (attributed lower forecast income of women to extrinsic social learning factors)
Number of subjects: 100
Study: 10493680

Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels during attacks (FMF‐a)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels during remission (FMF‐r)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IL‐8 levels during attacks (FMF‐a)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IL‐8 levels during remission (FMF‐r)
Number of subjects: 30

Group type: COMPARATOR
Intervention: sICAM‐1 levels in healthy controls (HC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: IL‐8 levels in healthy controls (HC)
Number of subjects: 30
Study: 8730011

Group type: EXPERIMENTAL
Intervention: Exponential model
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Linear model
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Extrapolated values (both models)
Number of subjects: 832
Study: 2069776

Group type: EXPERIMENTAL
Intervention: 400 mg caffeine
Number of subjects: 25
Study: 6131080

Group type: EXPERIMENTAL
Intervention: Lormetazepam 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lormetazepam 1.0 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lormetazepam 1.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lormetazepam 2.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Withdrawal after lormetazepam
Number of subjects: 0
Study: 30857523

Group type: EXPERIMENTAL
Intervention: Knowledge of reproductive health and available services
Number of subjects: 383
Study: 29052344

Group type: EXPERIMENTAL
Intervention: Counselling after home-based HIV counselling and testing (HBHCT) at one and two months
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group (HBHCT and referral only)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 302
Study: 26096318

Group type: EXPERIMENTAL
Intervention: Task-Based Mirror Therapy (TBMT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard motor rehabilitation
Number of subjects: 33
Study: 25162920

Group type: EXPERIMENTAL
Intervention: Transfusion of autologous leukoreduced blood stored for 40 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Transfusion of autologous leukoreduced blood stored for 3 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Transfusion of 40-day blood while breathing 80 ppm nitric oxide
Number of subjects: 14
Study: 21937893

Group type: EXPERIMENTAL
Intervention: Activity specific exercise program
Number of subjects: 82

Group type: COMPARATOR
Intervention: Walking program
Number of subjects: 82

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 82
Study: 19737441

Group type: EXPERIMENTAL
Intervention: 15 mg mecamylamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17691588

Group type: EXPERIMENTAL
Intervention: Iron(III)-hydroxide polymaltose complex (IPC, Maltofer) with tetracycline (2 x 250 mg capsules)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Tetracycline alone (2 x 250 mg capsules)
Number of subjects: 22
Study: 12576956

Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (6 mg/hr continuous infusion for 60 mins)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (normal saline, 6 mL/hr continuous infusion)
Number of subjects: 36
Study: 10230810

Group type: EXPERIMENTAL
Intervention: Citrus flavonoid supplementation (about 1g/day, 3 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8723850

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (5 mg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intramuscular diazepam (10 mg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Intravenous midazolam (7.5 mg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Intravenous diazepam (30 mg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam and diazepam
Number of subjects: 4
Study: 1678203

Group type: EXPERIMENTAL
Intervention: Ritanserin 5 mg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6219149

Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study: 31013851

Group type: COMPARATOR
Intervention: Low-dose CW (300 mg/d)
Number of subjects: 84

Group type: COMPARATOR
Intervention: High-dose CW (600 mg/d)
Number of subjects: 84
Study: 28601822

Group type: EXPERIMENTAL
Intervention: Workshop on decluttering and organising plus a visit from a professional cleaning company.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (only visit from a professional cleaning company).
Number of subjects: 60
Study: 26753640

Group type: EXPERIMENTAL
Intervention: Delayed extended-release formulation containing alpha-benzopyrone (Coumarin), benzo-gamma-pyrone (Troxuretina), and oligomeric proanthocyanidins from Vitis vinifera (OPC) in addition to compression therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard therapy with manual lymphatic drainage and compression)
Number of subjects: 0
Study: 23164597

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 35
Study: 20825373

Group type: EXPERIMENTAL
Intervention: Weekly severity ratings of manic symptoms
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Weekly severity ratings of depressive symptoms
Number of subjects: 236
Study: 19325997

Group type: EXPERIMENTAL
Intervention: 0.25 microg oral alphacalcidol twice daily for 6 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 19
Study: 16825679

Group type: EXPERIMENTAL
Intervention: Fish oils (4 g/d)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/d)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of Fish oils and Atorvastatin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15039131

Group type: EXPERIMENTAL
Intervention: Internal thoracic arteries from patients with LMS
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Radial arteries from patients with LMS
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Long saphenous veins from patients with LMS
Number of subjects: 74

Group type: COMPARATOR
Intervention: Internal thoracic arteries from patients with non-LMS
Number of subjects: 74

Group type: COMPARATOR
Intervention: Radial arteries from patients with non-LMS
Number of subjects: 74

Group type: COMPARATOR
Intervention: Long saphenous veins from patients with non-LMS
Number of subjects: 74
Study: 10614892

Group type: EXPERIMENTAL
Intervention: Computer-assisted management of warfarin therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (physician-based management)
Number of subjects: 100
Study: 8943961

Group type: EXPERIMENTAL
Intervention: Patients with esophageal stricture
Number of subjects: 57

Group type: COMPARATOR
Intervention: Matched controls with esophagitis
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Stricture patients
Number of subjects: 57
Study: 2018816

Group type: EXPERIMENTAL
Intervention: m-CPP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Metergoline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metergoline plus m-CPP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Metergoline pretreatment
Number of subjects: 12
Study: 6983315

Group type: EXPERIMENTAL
Intervention: Morphine (1 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Halothane and oxygen
Number of subjects: 18
Study: 31138278

Group type: EXPERIMENTAL
Intervention: Community-based randomized controlled trials (COPTR consortium)
Number of subjects: 1745

Group type: EXPERIMENTAL
Intervention: Recruitment strategies including careful planning, working with community partners, hiring culturally sensitive staff, and repeated contacts with potential participants
Number of subjects: 1745

Group type: EXPERIMENTAL
Intervention: 3-year commitment to the trial
Number of subjects: 1745
Study: 30301252

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of SRS and ICIs
Number of subjects: 0
Study: 26997655

Group type: EXPERIMENTAL
Intervention: Low-dose VPA (800 mg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-dose VPA (1200 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 24586256

Group type: EXPERIMENTAL
Intervention: TRC150094 (50 mg once daily)
Number of subjects: 40
Study: 22696883

Group type: EXPERIMENTAL
Intervention: Mini-incision surgical technique distal to the flexor crease (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mini-incision surgical technique proximal to the flexor crease (Group 2)
Number of subjects: 90
Study: 20061421

Group type: EXPERIMENTAL
Intervention: GH + Ox 0.03 mg/kg . d
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: GH + Ox 0.06 mg/kg . d
Number of subjects: 133

Group type: COMPARATOR
Intervention: GH + Pl
Number of subjects: 133
Study: 18052700

Group type: EXPERIMENTAL
Intervention: Meloxicam, 15 mg daily for 4 days starting the day before surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tenoxicam, 20 mg daily for 4 days starting the day before surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (Meloxicam and Tenoxicam)
Number of subjects: 100
Study: 16037892

Group type: COMPARATOR
Intervention: Dehydration (2.1% to 2.6% body mass loss)
Number of subjects: 6
Study: 12105159

Group type: EXPERIMENTAL
Intervention: cTnT-positive patients
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: TMPG 0/1
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: TMPG 0/1 flow
Number of subjects: 310
Study: 11692346

Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (water spray)
Number of subjects: 88
Study: 8626879

Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 8
Study: 2239934

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) therapy for 18 +/- 6 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) therapy
Number of subjects: 8
Study: 31473505

Group type: EXPERIMENTAL
Intervention: Meal, Ready-to-Eat (MRE) diet for 21 days followed by usual diet for 10 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group consuming usual ad libitum diet for 31 days
Number of subjects: 60
Study: 27867128

Group type: EXPERIMENTAL
Intervention: Meropenem 2 g every 8 hours
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Meropenem 1 g every 8 hours
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Meropenem 1 g every 6 hours
Number of subjects: 82
Study: 25849469

Group type: EXPERIMENTAL
Intervention: Meperidine in conjunction with lidocaine in intraligamentary injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (lidocaine alone)
Number of subjects: 0
Study: 24205050

Group type: EXPERIMENTAL
Intervention: Combined intervention (nutrition education and physical activity)
Number of subjects: 8301

Group type: COMPARATOR
Intervention: Control group (shared common control for nutrition and PA)
Number of subjects: 8301

Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 8301

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 8301

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 8301
Study: 21480203

Group type: EXPERIMENTAL
Intervention: Healthy Expressions group (n = 25)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (control group; n = 15)
Number of subjects: 40
Study: 19057400

Group type: EXPERIMENTAL
Intervention: below-knee compression stockings
Number of subjects: 21

Group type: COMPARATOR
Intervention: running socks
Number of subjects: 21
Study: 16555941

Group type: EXPERIMENTAL
Intervention: 375 ml of white wine daily
Number of subjects: 42